Publicaciones en colaboración con investigadores/as de Vall d'Hebron Institut de Recerca (32)

2023

  1. Association of magnetic resonance imaging phenotypes and serum biomarker levels with treatment response and long-term disease outcomes in multiple sclerosis patients

    European Journal of Neurology

  2. Myelin Oligodendrocyte Glycoprotein Antibodies in Adults with a First Demyelinating Event Suggestive of Multiple Sclerosis

    Annals of Neurology

  3. Primary Central Nervous System Vasculitis Following Alemtuzumab Treatment for Multiple Sclerosis: A Case Report and Literature Review

    Neurologist, Vol. 28, Núm. 4, pp. 270-272

  4. The CYP24A1 gene variant rs2762943 is associated with low serum 1,25-dihydroxyvitamin D levels in multiple sclerosis patients

    European Journal of Neurology, Vol. 30, Núm. 8, pp. 2401-2410

2022

  1. Correction to: Impact of COVID-19 pandemic on frequency of clinical visits, performance of MRI studies, and therapeutic choices in a multiple sclerosis referral centre (Journal of Neurology, (2022), 269, 4, (1764-1772), 10.1007/s00415-021-10958-z)

    Journal of Neurology

  2. Genomic Multiple Sclerosis Risk Variants Modulate the Expression of the ANKRD55–IL6ST Gene Region in Immature Dendritic Cells

    Frontiers in Immunology, Vol. 12

  3. Humoral and Cellular Responses to SARS-CoV-2 in Convalescent COVID-19 Patients With Multiple Sclerosis

    Neurology(R) neuroimmunology & neuroinflammation, Vol. 9, Núm. 2

  4. Impact of COVID-19 pandemic on frequency of clinical visits, performance of MRI studies, and therapeutic choices in a multiple sclerosis referral centre

    Journal of Neurology, Vol. 269, Núm. 4, pp. 1764-1772

  5. Is humoral and cellular response to SARS-CoV-2 vaccine modified by DMT in patients with multiple sclerosis and other autoimmune diseases?

    Multiple Sclerosis Journal, Vol. 28, Núm. 7, pp. 1138-1145

  6. Menopause does not modify disability trajectories in a longitudinal cohort of women with clinically isolated syndrome and multiple sclerosis followed from disease onset

    European Journal of Neurology, Vol. 29, Núm. 4, pp. 1075-1081

  7. Oral contraceptives do not modify the risk of a second attack and disability accrual in a prospective cohort of women with a clinically isolated syndrome and early multiple sclerosis

    Multiple Sclerosis Journal, Vol. 28, Núm. 6, pp. 950-957

  8. Peripheral myeloid-derived suppressor cells are good biomarkers of the efficacy of fingolimod in multiple sclerosis

    Journal of Neuroinflammation, Vol. 19, Núm. 1

  9. The kappa free light chain index and oligoclonal bands have a similar role in the McDonald criteria

    Brain : a journal of neurology, Vol. 145, Núm. 11, pp. 3931-3942

2021

  1. COVID-19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response

    European Journal of Neurology, Vol. 28, Núm. 10, pp. 3384-3395

  2. Chitinase 3-like 1 is not a target antigen in patients with multiple sclerosis

    Multiple Sclerosis Journal, Vol. 27, Núm. 9, pp. 1455-1457

  3. Developing a digital solution for remote assessment in multiple sclerosis: From concept to software as a medical device

    Brain Sciences, Vol. 11, Núm. 9

  4. Effect of Changes in MS Diagnostic Criteria Over 25 Years on Time to Treatment and Prognosis in Patients With Clinically Isolated Syndrome

    Neurology, Vol. 97, Núm. 17, pp. e1641-e1652

  5. Role of B Cell Profile for Predicting Secondary Autoimmunity in Patients Treated With Alemtuzumab

    Frontiers in Immunology, Vol. 12

2020

  1. A pharmacogenetic study implicates NINJ2 in the response to Interferon-β in multiple sclerosis

    Multiple Sclerosis Journal, Vol. 26, Núm. 9, pp. 1074-1082

  2. NLRP3 inflammasome as prognostic factor and therapeutic target in primary progressive multiple sclerosis patients

    Brain : a journal of neurology, Vol. 143, Núm. 5, pp. 1414-1430